AGC Biologics has acquired Molecular Medicine S.p.A. (“MolMed”), the leading-edge cell & gene therapy company in Milan, Italy. MolMed is a biotechnology company focused on research, development, production and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases.
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), providing world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells.
Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast track projects for orphan drugs and rare diseases.
The cell & gene therapy race is crowded with drug developers fighting for funding, seeking ways to differentiate themselves and vying for market approval.
To win, you need the right partner. We accelerate your race to GMP and run side-by-side with you every step of the way.
AGC Biologics has purchased a state-of-the-art commercial manufacturing facility in Boulder, Colorado, U.S.A., which will provide AGC Biologics with additional capacity and significantly larger production scale. We expect to begin full-scale operations and manufacturing by April 2021 and are currently staffing several new positions.
We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan.Learn More